Gilead Sciences reports positive long-term data for HIV drug Genvoya

Gilead Sciences has announced long-term clinical trial data that highlights the sustainable benefits offered by its HIV therapy Genvoya.

Results from two phase III trials, dubbed Study 104 and Study 111, have demonstrated the safety and efficacy of the combination therapy in tackling HIV-1 infection in treatment-naive adults over 144 weeks.

The regimen – which combines elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide – showed a significantly higher rates of virologic suppression compared to another Gilead combination therapy Stribild, which features the same ingredients in different doses.

Patients receiving Genvoya also demonstrated favourable renal and bone laboratory parameters compared to those treated with Stribild.

Dr Jose Arribas, associated professor of medicine at Spain's Hospital La Paz, said: "These study results further demonstrate that Genvoya provides durable viral suppression and has a demonstrated safety profile for long-term use by a range of appropriate HIV patients."

Genvoya has been approved for use in Europe since the end of 2015 for use among adult and paediatric HIV patients aged 12 years and older.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.